PACIRA PHARMACEUTICALS,INC. (NASDAQ:PCRX) Files An 8-K Other Events
Item 8.01. Other Events.
On March6, 2017, Pacira Pharmaceuticals,Inc. (the Company)
announced the proposed offering of Convertible Senior Notes due
2022 in a private placement to qualified institutional buyers to
Rule144A under the Securities Act of 1933, as amended (the
Securities Act). A copy of the press release announcing the
proposed offering of the notes is attached hereto as Exhibit99.1
and is incorporated herein by reference.
On March7, 2017, the Company announced the pricing of its
offering of $300 million aggregate principal amount of 2.375%
Convertible Senior Notes due 2022 in a private placement to
qualified institutional buyers to Rule144A under the Securities
Act. A copy of the press release announcing the pricing of the
notes is attached hereto as Exhibit99.2 and is incorporated
herein by reference.
Item 9.01. Financial Statements and
Exhibits.
(d)Exhibits.
|
Exhibit No. |
|
Description |
|
99.1 |
Press Release dated March6, 2017, announcing the offering |
|
|
99.2 |
Press Release dated March7, 2017, announcing the pricing of |
About PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX)
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX) Recent Trading Information
PACIRA PHARMACEUTICALS, INC. (NASDAQ:PCRX) closed its last trading session up +0.20 at 48.65 with 1,653,930 shares trading hands.
